ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B Without Inhibitory Antibodies to Factor VIII or IX
Enrolling By Invitation
99 years or below
All
Phase
3
1 participants needed
1 Location
Brief description of study
This study will evaluate the efficacy and safety of fitusiran compared to on-demand treatment with factor concentrates, as determined by the frequency of bleeding episodes in enrolled patients.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Hemophilia
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 828210
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
